email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2638-5910

Archives of Diabetes & Obesity

Mini Review(ISSN: 2638-5910)

Beyond glucose control agents: Sodium-Glucose Co-transporter 2 Inhibitors in Heart failure Volume 3 - Issue 4

Nikolaos Karamichalakis*

  • Department of Cardiology, Hygeia Hospital, Greece

Received:May 31, 2021;   Published: June 10, 2021

Corresponding author: Nikolaos Karamichalakis, Department of Cardiology, Hygeia Hospital, Athens, Greece

DOI: 10.32474/ADO.2021.03.000167

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

HF and T2D often coexist and the maleficent effects of this coupling prompted the US Food and Drug Administration to set hypoglycaemic drugs clinical trials, designed to rule out cardiovascular harm and promote cardioprotection in the year 2008 [1]. In the line of this strategic motivation, cardiovascular outcome trials (CVOTs) with a novel class of hypoglycaemic drugs, the sodium-glucose co-transporter 2 (SGLT2) inhibitors, emerged and surprisingly demonstrated positive cardiovascular outcomes, mainly due to a decline in heart failure (HF) risk. The EMPAREG OUTCOME trial with empagliflozin, the CANVAS Program with canagliflozin

Introduction| SGLT2 Inhibitors and Heart Failure: The Clinical Trials| Metanalyses and Real-World Data| Conclusion| References|